+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Basal Cell Carcinoma Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896176
  • Report
  • January 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc
  • Mylan N.V.
  • Perrigo Company plc
  • Sun Pharmaceuticals Ltd
  • MORE
Market Overview

The basal cell carcinoma treatment market is anticipated to grow with a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the market are the increasing prevalence of skin malignancies, rise in various environmental factors, which leads to more UV exposure and increasing geriatric population who are more susceptible to skin diseases. According to the Skin Cancer Foundation, about 90% of nonmelanoma skin cancers are correlated with exposure to ultraviolet radiation, and Basal cell carcinoma is the most common form of skin cancer. It is estimated that 4.3 million cases of BCC are diagnosed in the United States every year. However, high susceptibility of basal cell carcinoma to remain under-diagnosed and the high cost of the treatment are the constraints to the growth of the market.

Scope of the Report

Basal cell carcinoma is the type of skin cancer that begins in the basal cells, which produce new cells when the old ones die. The Basal Cell Carcinoma Treatment market is comprised of the Treatment Type, End-user, and Geography.

Key Market Trends

Surgery for Basal Cell Carcinoma is Expected to Be the Fastest-Growing Segment
  • The most common method used for the treatment of basal cell carcinoma is surgical excision. In this procedure, the surgeon cuts out the cancerous lesion and a surrounding margin of healthy skin. The surplus is inspected under a microscope to be sure there are no cancer cells.
  • Excision might be recommended for basal cell carcinomas that are less likely to recur, such as those that form on the chest, back, hands and feet.
  • Surgical excision has established to be more efficient due to its lowest possible recurrence rates, maximum cure rates, and top cosmetic results among all the treatment approach for basal cell carcinoma, leading to their high demand. It is expected that surgical excision to remain dominant over the next few years, confirming the dominance of the surgical segment.
  • According to the American Academy of Dermatology, it is expected that 95,830 noninvasive melanoma cases will be diagnosed in the United States in 2019, which pushes the growth of the market further.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall basal cell carcinoma treatment market, throughout the forecast period. This is due to the factors such as the rising incidence of geriatric population, rising awareness of advanced treatments, favorable reimbursement scenario, high prevalence of basal cell carcinoma in this region. In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of basal cell carcinoma in the country, is anticipated to stimulate the demand in this region. According to the American Academy of Dermatology, it is estimated that approximately 9,500 people in the United States are diagnosed with skin malignancies every day. Thus, rising cases of the skin malignancies expected propel the growth of the market.

Competitive Landscape

The Basal Cell Carcinoma Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Merck & Co. Inc., Bausch Health Companies, F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan Inc., Perrigo Company plc, Strides Arcolab Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan, Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc
  • Mylan N.V.
  • Perrigo Company plc
  • Sun Pharmaceuticals Ltd
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing prevalence of Skin cancers
4.2.2 Increase in geriatric population
4.2.3 Environmental factors leading to greater exposure of UV radiation
4.3 Market Restraints
4.3.1 High cost of treatment
4.3.2 High Susceptibility of Basal Cell Carcinoma to remain Under-diagnosed
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Surgery
5.1.2 Medication
5.1.3 Others
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co. Inc
6.1.2 Bausch Health Companies Inc.
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Sun Pharmaceuticals Ltd
6.1.5 Mylan N.V.
6.1.6 Allergan, Inc.
6.1.7 Perrigo Company plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co. Inc
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Sun Pharmaceuticals Ltd
  • Mylan N.V.
  • Allergan, Inc.
  • Perrigo Company plc
Note: Product cover images may vary from those shown
Adroll
adroll